Company: NCNA
Filing Date: 2025-04-04
Form Type: DRS
Source: 0000950123-25-003335
Chunk: 4

Company: NuCana plc
Filing Date: 2025-04-04
Form: DRS
Chunk 4
---
 to develop. We do not intend to list the Warrants or Pre-Funded Warrants on The
Nasdaq Capital Market, any other national securities exchange or any other trading system. Without an active trading market, the liquidity of the Warrants and the Pre-Funded Warrants will be limited. We
anticipate that the ADSs to be issued upon exercise of the Warrants and the Pre- Funded Warrants will trade on The Nasdaq Capital Market.

Confidential Treatment Requested by Nucana plc Pursuant to 17 C.F.R. Section 200.83 We have engaged Laidlaw & Company (UK) Ltd., or Laidlaw, to act as the placement agent, or the Placement Agent, in connection with this offering. The Placement Agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The Placement Agent is not purchasing or selling any of the securities we are offering and the Placement Agent is not required to arrange the purchase or sale of any specific number or dollar amount of securities. There is no required minimum number of securities that must be sold as a condition to closing this offering, and there are no arrangements to place the funds in an escrow, trust, or similar account. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund if we do not sell all of the securities offered hereby. This offering will terminate on , 2025, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. We have agreed to pay the Placement Agent the Placement Agent fees as set forth in the table below, which assumes we sell all of the securities offered by this prospectus. See “Plan of Distribution” on page 66 of this prospectus for more information regarding these arrangements. Investing in our ADSs involves a high degree of risk. See “ Risk Factors” beginning on page 7 of this prospectus and in the other documents that are incorporated by reference herein before purchasing any of the securities offered by this prospectus. Neither the U.S. Securities and Exchange Commission, or SEC, nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

|                            |     | Per